Heart

Non-atherosclerotic myocardial infarction in hypereosinophilic syndrome: emerging insights and therapeutic approaches

Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...
Kauppalehti

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Le Lézard

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b ...

Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at AASLD's The Liver Meeting®, in ...

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Le Lézard

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran ...

Vir Biotechnology, Inc. today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly ...

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.